* Cases of prolonged survival with improvements in hematological parameters were noted in
both acute myeloid leukemia (AML) and multiple myeloma (MM) patients
The post BRIEF-Celyad announces positive new data from its CAR-T NKR-2 Phase I Trial appeared first on NASDAQ.